

PRESS RELEASE

October 2, 2007

**Skanditeks subsidiary CMA Microdialysis AB launches system for continuous bedside glucose monitoring**

CMA Microdialysis AB (CMA) today announced the launch of the new CE-approved IView Catheter, which enables highly accurate tight glycemetic control (TGC) in the Intensive Care Unit (ICU).

Skanditek holds 78 percent of it's subsidiary CMA Microdialysis.

As to the rest, we refer to enclosed press release from CMA Microdialysis AB.

Stockholm, October 2, 2007

SKANDITEK INDUSTRIFÖRVALTNING AB (publ)

---

For further information, please contact:

Patrik Tigerschiöld, President and CEO,  
telephone +46-8-614 00 20,

Philip Siberg, CEO CMA Microdialysis,  
mobil +46 70 790 67 43, e-post [philip.siberg@microdialysis.se](mailto:philip.siberg@microdialysis.se)

Skanditek is an industrial holding company owning stock in Swedish companies. The business concept is to be an active and long-term stockholder and to further the portfolio companies' development by providing industrial and financial competence at board and management level. The portfolio comprises 9 companies within technology, biotechnology and services. The major holdings are in Bure Equity (17%), MYDATA automation (95%), PartnerTech (36%),and Vitrolife (25%). Skanditek is listed on the OMX Nordic List.

## **CMA launches system for continuous bedside glucose monitoring.**

STOCKHOLM 2<sup>nd</sup> October 2007

**CMA Microdialysis AB (CMA) today announced the launch of the new CE-approved IView Catheter, which enables highly accurate tight glycemic control (TGC) in the Intensive Care Unit (ICU).**

Several large clinical studies have proven that an accurate and efficient implementation of TGC can lead to significantly reduced mortality rates. The Belgian physician Greet Van den Berghe has reported reduced ICU mortality of up to 34% following a TGC protocol.

In the US alone, there are approximately 6,000 intensive care units managing roughly 55,000 patients per day. According to research from Johns Hopkins Bloomberg School of Public Health, fully implemented TGC would potentially save 150,000 lives annually in the US and create \$18 billion in total savings in US health-care expenditures annually.

“TGC is one of the biggest advances in critical care medicine in many years. CMA’s unique system brings a solution to ICU’s that are seeking continuous, easy-to-use and accurate alternatives to repeated needle punctures.” says Philip Siberg, CEO of CMA Microdialysis AB.

The unique CMA 64 IView Catheter is sterile single-use, minimally invasive device, which allows for continuous sampling of energy metabolites in the peripheral veins. Accurate values of systemic Glucose, Lactate, Pyruvate, Urea and other diagnostic markers can be monitored bedside.

The IView catheter is applied using a standard peripheral vein catheter (PVC) for simple and safe introduction. The catheter can be used for intravenous monitoring during surgery, intensive care and in general wards. The IView Catheter has proven to have an outstanding accuracy in blood. The diffusing membrane has been specifically developed and treated to maintain the highest accuracy for up to three days.

The catheter is approved for use with CMA’s existing suite of Microdialysis analyzers and accessories. A wide range of substances and free fractions of drugs can be monitored using the IView catheter. The clean samples and possibility for frequent sampling without discomfort for the patient makes it ideal for clinical research.

Microdialysis is a technique, which is used routinely in neuro intensive care, plastic surgery and transplantation to monitor specific tissues for early signs of complications. Following 10 years of product development in Microdialysis, the new IView Catheter brings a revolution in systemic blood monitoring.

For more information, product notes, and pictures please contact:

Philip Siberg, CEO  
Tel +46 70 790 6734  
E-mail: [philip.siberg@microdialysis.se](mailto:philip.siberg@microdialysis.se)

Sven Burman, Product Manager  
Tel +46 8 470 10 63  
E-mail: [sven.burman@microdialysis.se](mailto:sven.burman@microdialysis.se)

---

About CMA Microdialysis AB

*CMA Microdialysis is the leading company devoted to the development, manufacturing and marketing of the Microdialysis technique. The company was formed in 1984 and was the first company in the world to market Microdialysis products and know-how. Consumables, instruments and computer software are sold to universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling and diagnostics of organs and tissues. CMA has offices in Sweden, USA and Germany and distributors in 28 countries. For more information see [www.microdialysis.com](http://www.microdialysis.com)*